Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Mylan Receives Health Canada Approval For Generic Cristor

RELATED NEWS
Trade MYL now with 
3/15/2012 5:31 PM ET

Mylan Pharmaceuticals ULC, the Canadian unit of Mylan Inc. (MYL: Quote) said Thursday that it received approval from Health Canada for Mylan-Rosuvastatin Calcium Tablets, 5mg, 10mg, 20mg and 40mg.

According to IMS Health, sales of Rosuvastatin Calcium Tablets in Canada was about C$742 million for the year ended Dec. 31, 2011.

Mylan-Rosuvastatin is the generic version of Astra Zeneca Plc's (AZN) Crestor Tablets. The drug is used for the management of primary hypercholesterolaemia, mixed dyslipidaemia, and familial hypercholesterolaemia.

Click here to receive FREE breaking news email alerts for Mylan Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Starbucks Corp. said Thursday after the markets closed that its second quarter profit rose 9.4% from last year, helped by higher revenue. The company's quarterly earnings per share came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. The world's largest specialty coffee retailer also raised its full year earnings outlook. Software giant Microsoft Corp. said Thursday after the markets closed that its third quarter profit fell 6.6% from last year, when results were boosted by special upgrade offer revenues. However, the company's quarterly earnings per share came in above analysts' expectations as did its quarterly revenue. Apple Inc. said Wednesday after the markets closed that its second quarter profit rose 7% from last year, as sales surged and margins improved amid strong sales of its iPhones. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly revenue. At the same time, the company gave a slightly downbeat revenue forecast for the current quarter.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.